Investing Profile

Heather Roxborough

InvestorVC
Senior Partner at Oxford Science Enterprises
Photo of Heather Roxborough, Senior Associate at Oxford Science Enterprises

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Johnson & Johnson Network
77 CONNECTIONS
Unilever Network
67 CONNECTIONS
Unilever Network
67 CONNECTIONS
Unilever Network
67 CONNECTIONS
Optum Ventures Network
19 CONNECTIONS
cb
$100K - $5.0M
$1.5M
9
CompanyStageDateRound SizeTotal Raised
Neu Health
SeedJan 2025$2M
$2M
Amber Therapeutics
Series AJun 2024$100M
$100M
Co-investors: Tiffany Le (New Enterprise Associates (NEA)), Ali Behbahani (New Enterprise Associates (NEA)), Kevin Chu (F-Prime Capital Partners), Caroline Gaynor (Lightstone Ventures)
Navenio
Series ASep 2023$6M
Series UnknownDec 2021$13M
$46M
Co-investors: Ed Phillips (Future Planet Capital)
Caristo Diagnostics
Series AApr 2023$16M
$16M
Co-investors: Ian Downing (BGF Ventures)
Kaia Health
Series CApr 2021$75M
Series BJun 2020$26M
Series ASep 2019$8M
$150M
Co-investors: Antoine Zins (Eurazeo), Roman Scharf (3VC), Peter Lasinger (3VC), Christian Jepsen (Heartcore Capital), James Wise (Balderton Capital), Florian Huber (EWOR)
icometrix
Series AMay 2019$18M
$18M
COMEDY CLUBS
Post-doctoral Fellow King's College LondonPresent
Research Manager UnileverPresent
Team Leader UnileverPresent
Associate UnileverPresent
Foresighting ITI Life SciencesPresent
Principal Tate & LylePresent
Partner Optum VenturesPresent
Senior Partner Oxford Science EnterprisesPresent
Senior Director, New Ventures & Transactions Johnson & Johnson2017 - 2018
Principal Tate & Lyle Ventures2013 - 2016
Investment Manager Mercia Asset Management PLC2010 - 2013
Queen's University Belfast PhD Clinical Biochemistry
Queen's University Belfast BSc (Hon) Biochemistry (1st class)
Sign in with Google →
Sign in with Google →